Kristina Burow is a member of the board of directors at VIR. Since 2002, she has served as a managing director at ARCH Venture Partners, where she focuses on building innovative companies in multiple areas including biotechnology, pharmaceuticals, ag-biotech and alternative energy.
Ms. Burow co-founded Receptos (RCPT, acquired by Celgene (CELG)) and Sapphire Energy and currently serves as a director of Lycera, BlackThorn Therapeutics, Metacrine, Unity Biotechnology, AgBiome, Scholar Rock, Aledade, Sienna Biopharmaceuticals and Trelys. She has participated in the funding and development of several other portfolio companies including Kura Oncology (KURA), Siluria Technologies, Kythera Biopharmaceuticals (KYTH, acquired by Allergan (AGN)), Ikaria (acquired by Mallinckrodt (MNK)), Achaogen (AKAO), Quanterix, Aledade, Ensemble Therapeutics, and Accelerator Corporation.
Prior to ARCH, Ms. Burow was an associate with the Novartis BioVenture Fund in San Diego where she was involved in numerous investments in the life science sector. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed chemistry operations and was active in business development helping spin out numerous companies.
Ms. Burow holds an M.B.A. from the University of Chicago, an M.A. in chemistry from Columbia University and a B.S. in chemistry from the University of California, Berkeley.